Clinical stage drug development company Telik has reported a net loss of $1.88m, or $0.78 per share, for the third quarter ended 30 September 2012 compared to a net loss of $2.85m, or $1.58 per share, for the third quarter ended 30 September 2011.
Loss from operations for third quarter of 2012 was $1.88m compared to loss from operations of $2.85m for the third quarter of 2011.
The company reported a net loss of $6.20m, or $3.07 per share, for the nine months ended 30 September 2012 compared to a net loss of $9.52m, or $5.30 per share, for the nine months ended 30 September 2011.
Loss from operations of $6.21m was reported for the first nine months of 2012 compared to loss from operations of $9.55m for the first nine months of 2011.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/telik-q3-net-loss-narrows-121112
